Assessing Kestra Medical Technologies (KMTS) Valuation After Recent Share Price Momentum

Kestra Medical Technologies (KMTS) has drawn investor attention after recent trading left the shares around $22.23, with a mixed return profile across the past week, month and past 3 months.

See our latest analysis for Kestra Medical Technologies.

The recent 14.23% 1 month share price return contrasts with weaker year to date share price performance of 8.86% and a 1 year total shareholder return of 11.50%. This suggests short term momentum has picked up while longer term returns remain under pressure.

If this kind of rebound has your attention, it may be a good moment to look across the sector using our screener for 32 healthcare AI stocks

With Kestra Medical Technologies trading around $22.23 and sitting roughly 25% below one set of analyst price targets, the key question is whether this reflects undervaluation or whether the current price already captures future growth potential.

Most Popular Narrative: 24% Undervalued

With Kestra Medical Technologies last closing at $22.23 versus a narrative fair value of about $29.14, the current setup centers on growth expectations that stretch well beyond today’s losses.

Category underpenetration in the U.S. with only 14% of eligible patients currently using a wearable defibrillator creates a long runway for adoption, supporting sustained double digit prescription growth and accelerating revenue expansion.

Read the complete narrative.

Curious what kind of revenue ramp and margin shift need to sit behind that fair value? The narrative leans on aggressive top line gains and a future profitability profile that looks very different to today. The key moving parts are clear, but the exact mix of growth, scale and pricing power is not.

At the core of this most followed narrative is the assumption that a relatively small revenue base of $83.7 million can compound rapidly, while annual net losses of $148.1 million narrow over time. The valuation work is built using a discount rate of 7.7%, with revenue growth, future earnings and a premium earnings multiple all feeding into a fair value of roughly $29.14 per share.

Result: Fair Value of $29.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on wider wearable defibrillator adoption and stronger payer contracts; stalled guidelines or weaker reimbursement could quickly undermine that 24% undervalued story.

Find out about the key risks to this Kestra Medical Technologies narrative.

Another View: Price Tag Looks Stretched

That 24% undervalued fair value sits awkwardly next to the current P/S of 15.5x, which is far above the US Medical Equipment industry at 3x, peers at 2.2x and even the fair ratio of 3.9x. If growth disappoints, how much room is there before sentiment flips?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both optimism and concern in this story, it makes sense to look at the numbers yourself, decide quickly where you stand before sentiment shifts, and then weigh up the 1 key reward and 1 important warning sign

Looking for more investment ideas?

If Kestra has sparked your interest, do not stop here. Broaden your watchlist with other focused stock ideas that could suit different roles in your portfolio.

• Target potential mispriced opportunities by scanning companies that look cheap relative to quality using our 53 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that offer resilient payouts through the 13 dividend fortresses.
• Prioritize capital protection by checking companies that score well on stability and financial resilience via the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com